Systemic Treatments for Lung Cancer Patients Receiving Hemodialysis.

Autor:	Leung TV; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Hughes ME; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Cambareri CG; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Rubin DJ; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Eaby-Sandy B; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Jazyk:	angličtina
Zdroj:	Journal of the advanced practitioner in oncology [J Adv Pract Oncol] 2018 Sep-Oct; Vol. 9 (6), pp. 614-629. Date of Electronic Publication: 2018 Sep 01.
Abstrakt:	Chemotherapy, and now targeted therapies and immunotherapies, are widely used for the management of patients with all stages of lung cancer. Some challenges present when patients are receiving concomitant hemodialysis for various comorbid conditions. However, this should not immediately rule out a patient for treatment. Many drugs may be safely given to patients who are receiving hemodialysis with the proper dosing schedule and careful monitoring. This article will outline the current literature surrounding the use of these drugs in patients undergoing active hemodialysis while being treated for lung cancer.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu